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Background
TRAIL, a member of the TNF ligand family, was shown to
selectively kill cancer cells and, therefore, to participate in
the cell-mediated immunity against tumors. However,
TRAIL is down-regulated in a variety of cancers. Further-
more, PRAME (preferentially expressed antigen of mela-
noma) is frequently over expressed in a wide variety of
malignant diseases. It was shown that PRAME, in a com-
plex with a member of the polycomb group, EZH2, can
function as a transcriptional repressor of retinoic acid
receptor. Interestingly, TRAIL expression can be positively
regulated by retinoic acid. Previous studies performed by
us revealed that TRAIL is down-regulated and PRAME is
up-regulated during development of chronic myeloid leu-
kemia (CML) and that their normal levels are restored
after complete cytogenetic remission (CCR). There was a
significant, negative correlation between the expression of
PRAME and TRAIL in CML patients. Over expression of
BCR-ABL in the acute promyelocytic leukemia cell line
HL-60 increased the levels of PRAME and decreased the
levels of TRAIL. Knocking-down of either PRAME
or EZH2 in K562 CML cell line resulted in TRAIL
up-regulation.
Materials and methods
We are continuing this study in solid tumors and sarco-
mas, through qRT-PCR and tissue microarray (TMA)
immunohistochemistry, using samples from human cell
lines and cancer patients.
Results
Using the publicly available Oncomine Research platform,
we found that PRAME was up- and TRAIL was down-
regulated in several cancers. Literature data were validated
by TMA immunohistochemistry, in tumor samples from
patients with lung, prostate, breast and kidney cancers,
melanoma and sarcoma. We are performing qRT-PCR
assays to validate deregulated mRNA expression in several
tumor cell lines and primary patient samples.
Conclusions
These initial data, showing PRAME overexpressed in
tumors, accompanied by a decreased expression of TRAIL,
corroborate our hypothesis that the presence of a complex
consisting of PRAME and EZH2 is responsible for the
negative transcriptional regulation of TRAIL in cancer.
Financial support
FAPESP and CNPq.
Acknowledgements
We thank the Department of Pathologic Anatomy and the International
Center for Research, from AC Camargo Hospital for the tissue microarray
assays and for the donation of cancer cell lines, respectively. We thank Dr.
René Bernards (Amsterdam, The Netherlands) for the gift of PRAME and
EZH2 short hairpin RNA vectors.
Author details
1Department of Immunology, Sao Paulo University, São Paulo, Brazil.
2Department of Pathologic Anatomy, AC Camargo Hospital, São Paulo, SP, Brazil.
Published: 4 April 2013
doi:10.1186/1753-6561-7-S2-P10
Cite this article as: Mello et al.: Regulation of TRAIL expression by
PRAME and EZH2 as potential therapeutic target against solid tumors.
BMC Proceedings 2013 7(Suppl 2):P10.
* Correspondence: gpam@usp.br
1Department of Immunology, Sao Paulo University, São Paulo, Brazil
Full list of author information is available at the end of the article
Mello et al. BMC Proceedings 2013, 7(Suppl 2):P10
http://www.biomedcentral.com/1753-6561/7/S2/P10
© 2013 Mello et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
